Pre-exposure prophylaxis (PrEP)
GPTKB entity
Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medical intervention
|
| gptkbp:administeredBy |
oral medication
injectable medication |
| gptkbp:alternativeName |
gptkb:PrEP
pre-exposure prophylaxis |
| gptkbp:approvalYear |
2012
|
| gptkbp:approvedBy |
gptkb:U.S._Food_and_Drug_Administration
|
| gptkbp:commonHealthIssues |
gptkb:cabotegravir
tenofovir alafenamide/emtricitabine tenofovir disoproxil fumarate/emtricitabine |
| gptkbp:contraindication |
severe kidney disease
HIV-positive individuals |
| gptkbp:effect |
over 90% when taken as prescribed
|
| gptkbp:frequency |
daily (oral)
every 2 months (injectable) |
| https://www.w3.org/2000/01/rdf-schema#label |
Pre-exposure prophylaxis (PrEP)
|
| gptkbp:notEffectiveAgainst |
pregnancy
other sexually transmitted infections |
| gptkbp:recommendation |
gptkb:Centers_for_Disease_Control_and_Prevention
gptkb:World_Health_Organization |
| gptkbp:requires |
medical follow-up
regular HIV testing |
| gptkbp:sideEffect |
nausea
headache kidney function changes bone density loss |
| gptkbp:targetAudience |
people at high risk of HIV infection
|
| gptkbp:usedFor |
HIV prevention
|
| gptkbp:bfsParent |
gptkb:Sida
|
| gptkbp:bfsLayer |
7
|